Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DE-104 in primary open-angle glaucoma or ocular hypertension
NCT00657579Phase 2Completed
- Sponsor
- Santen Pharmaceutical
- Countries
- 1
01
Overview
A Phase 2 trial of omidenepag isopropyl in primary open-angle glaucoma (POAG), ocular hypertension, sponsored by Santen Pharmaceutical. Status: completed.
02
Drugs
omidenepag isopropyl
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT00657579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00657579.